Novartis catches chill as mask wearing keeps flu at bay
Updated / Tuesday, 27 Apr 2021
10:51
The Swiss drugmaker s first-quarter profit fell below analyst expectations
Mask wearing during the pandemic kept the flu largely at bay this year, dampening Novartis s generic cough medicines business and helping drag the Swiss drugmaker s first-quarter profit below analyst expectations.
Novartis today joined drugmakers including domestic rival Roche in reporting drug sales, including for cancer and eye disease, had taken a hit as people skipped visiting the doctor during the coronavirus crisis.
In addition a historically weak cough-and-cold season, kept in check by broad mask wearing and social distancing, further dented Novartis s Sandoz generics unit that is also grappling with persistent price pressure from rivals.
Novartis Pharma AG: Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth Group guidance for FY 2021 confirmed
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Quartalszahlen des Pharmakonzerns – Zurückhaltung der Patienten drückt Resultat von Novartis
berneroberlaender.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from berneroberlaender.ch Daily Mail and Mail on Sunday newspapers.
30 minutes
Monocle’s editorial director, Tyler Brûlé, is joined by Vas Narasimhan, CEO of Swiss pharmaceutical giant Novartis. One year on from their first discussion on ‘The Chiefs’, they assess the roadmap ahead, from vaccine rollout to reimagining medicine.
13 April 2021
Ein Jahr Leben mit Corona (2/10) - Was ich im Pandemiejahr gelernt habe – Vas Narasimhan: «Bahnbrechender Erfolg geschieht nur gemeinsam»
aargauerzeitung.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aargauerzeitung.ch Daily Mail and Mail on Sunday newspapers.